{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T22:35:08Z","timestamp":1793054108838,"version":"4.5.0"},"reference-count":63,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"name":"EQRx International, Inc"}],"content-domain":{"domain":["international-journal-of-gynecological-cancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Gynecological Cancer"],"published-print":{"date-parts":[[2023,11]]},"DOI":"10.1136\/ijgc-2023-004454","type":"journal-article","created":{"date-parts":[[2023,8,28]],"date-time":"2023-08-28T03:26:22Z","timestamp":1693193182000},"page":"1675-1681","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":22,"title":["Evolving treatment paradigms in metastatic or recurrent low-grade endometrial cancer: When is hormonal-based therapy the preferred option?"],"prefix":"10.1016","volume":"33","author":[{"given":"Haider","family":"Mahdi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2472-8306","authenticated-orcid":false,"given":"Isabelle","family":"Ray-Coquard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Domenica","family":"Lorusso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mansoor Raza","family":"Mirza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6985-0159","authenticated-orcid":false,"given":"Bradley J","family":"Monk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7241-3096","authenticated-orcid":false,"given":"Brian","family":"Slomovitz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1136\/ijgc-2023-004454_bb0010","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1016\/S0140-6736(15)00130-0","article-title":"Endometrial cancer","volume":"387","author":"Morice","year":"2016","journal-title":"Lancet"},{"key":"10.1136\/ijgc-2023-004454_bb0015","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1016\/j.annonc.2022.05.009","article-title":"Endometrial cancer: ESMO clinical practice guideline for diagnosis, treatment and follow-up","volume":"33","author":"Oaknin","year":"2022","journal-title":"Ann Oncol"},{"key":"10.1136\/ijgc-2023-004454_bb0020","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1136\/ijgc-2020-002230","article-title":"ESGO\/ESTRO\/ESP guidelines for the management of patients with endometrial carcinoma","volume":"31","author":"Concin","year":"2021","journal-title":"Int J Gynecol Cancer"},{"key":"10.1136\/ijgc-2023-004454_bb0025","unstructured":"Society AC . Cancer facts & figures 2023. American Cancer Society. n.d.Available: https:\/\/www.cancer.org\/research\/cancer-facts-statistics\/all-cancer-facts-figures\/2023-cancer-facts-figures.html"},{"key":"10.1136\/ijgc-2023-004454_bb0030","doi-asserted-by":"crossref","first-page":"1412","DOI":"10.1016\/S0140-6736(22)00323-3","article-title":"Endometrial cancer","volume":"399","author":"Crosbie","year":"2022","journal-title":"Lancet"},{"key":"10.1136\/ijgc-2023-004454_bb0035","doi-asserted-by":"crossref","first-page":"2053","DOI":"10.1056\/NEJMra1514010","article-title":"Endometrial cancer","volume":"383","author":"Lu","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1136\/ijgc-2023-004454_bb0040","author":"Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines\u00ae) for Uterine Neoplasms, Version 1.2023. \u00a9 National Comprehensive Cancer Network, Inc","year":"2023","journal-title":"To view the most recent and complete version of the guideline, go online to NCCN.Org. *NCCN makes no warranties of any kind whatsoever regarding their content, use or application and disclaims any responsibility for their application or use in any way"},{"key":"10.1136\/ijgc-2023-004454_bb0045","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1016\/j.ygyno.2006.02.011","article-title":"Follow-up after primary therapy for endometrial cancer: a systematic review","volume":"101","author":"Fung-Kee-Fung","year":"2006","journal-title":"Gynecol Oncol"},{"key":"10.1136\/ijgc-2023-004454_bb0050","doi-asserted-by":"crossref","first-page":"1296","DOI":"10.1038\/bjc.2016.337","article-title":"Predicting poor prognosis recurrence in women with endometrial cancer: a Nomogram developed by the FRANCOGYN study group","volume":"115","author":"Ouldamer","year":"2016","journal-title":"Br J Cancer"},{"key":"10.1136\/ijgc-2023-004454_bb0055","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1038\/nature12113","article-title":"Integrated Genomic characterization of endometrial carcinoma","volume":"497","author":"Cancer Genome Atlas Research Network","year":"2013","journal-title":"Nature"},{"key":"10.1136\/ijgc-2023-004454_bb0060","doi-asserted-by":"crossref","first-page":"3388","DOI":"10.1200\/JCO.20.00549","article-title":"Molecular classification of the PORTEC-3 trial for high-risk endometrial cancer: impact on prognosis and benefit from adjuvant therapy","volume":"38","author":"Le\u00f3n-Castillo","year":"2020","journal-title":"J Clin Oncol"},{"key":"10.1136\/ijgc-2023-004454_bb0065","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1002\/cncr.30496","article-title":"Confirmation of promise: A simple, Genomics-based clinical Classifier for endometrial cancer","volume":"123","author":"Talhouk","year":"2017","journal-title":"Cancer"},{"key":"10.1136\/ijgc-2023-004454_bb0070","doi-asserted-by":"crossref","first-page":"1180","DOI":"10.1093\/annonc\/mdy058","article-title":"Final validation of the promise molecular Classifier for endometrial carcinoma in a large population-based case series","volume":"29","author":"Kommoss","year":"2018","journal-title":"Ann Oncol"},{"key":"10.1136\/ijgc-2023-004454_bb0075","doi-asserted-by":"crossref","first-page":"4215","DOI":"10.1158\/1078-0432.CCR-15-2878","article-title":"Improved risk assessment by integrating molecular and Clinicopathological factors in early-stage endometrial cancer-combined analysis of the PORTEC cohorts","volume":"22","author":"Stelloo","year":"2016","journal-title":"Clin Cancer Res"},{"key":"10.1136\/ijgc-2023-004454_bb0080","doi-asserted-by":"crossref","DOI":"10.1136\/ijgc-2021-ESGO.137","article-title":"397\u2005molecular profiling of NSMP high-risk endometrial cancers of the PORTEC-3 trial \u2013 Prognostic refinement and Druggable targets","author":"Vermij","year":"2021","journal-title":"ESGO 2021 Congress"},{"key":"10.1136\/ijgc-2023-004454_bb0085","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1038\/s41416-018-0187-6","article-title":"L1Cam further Stratifies endometrial carcinoma patients with no specific molecular risk profile","volume":"119","author":"Kommoss","year":"2018","journal-title":"Br J Cancer"},{"key":"10.1136\/ijgc-2023-004454_bb0090","doi-asserted-by":"crossref","first-page":"1032","DOI":"10.1038\/modpathol.2017.15","article-title":"Ctnnb1 (beta-Catenin) Mutation identifies low grade, early stage endometrial cancer patients at increased risk of recurrence","volume":"30","author":"Kurnit","year":"2017","journal-title":"Mod Pathol"},{"key":"10.1136\/ijgc-2023-004454_bb0095","author":"Herrington","year":"2020"},{"key":"10.1136\/ijgc-2023-004454_bb0100","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1016\/j.ygyno.2021.09.018","article-title":"Prognostic impact of mismatch repair deficiency in high- and low-intermediate-risk, early-stage endometrial cancer following vaginal Brachytherapy","volume":"163","author":"Li","year":"2021","journal-title":"Gynecol Oncol"},{"key":"10.1136\/ijgc-2023-004454_bb0105","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/j.humpath.2020.12.003","article-title":"The cutoff for estrogen and progesterone receptor expression in endometrial cancer Revisited: a European network for individualized treatment of endometrial cancer collaboration study","volume":"109","author":"van Weelden","year":"2021","journal-title":"Hum Pathol"},{"key":"10.1136\/ijgc-2023-004454_bb0110","doi-asserted-by":"crossref","first-page":"1360","DOI":"10.1038\/s41416-023-02141-0","article-title":"Prognostic refinement of NSMP high-risk endometrial cancers using oestrogen receptor immunohistochemistry","volume":"128","author":"Vermij","year":"2023","journal-title":"Br J Cancer"},{"key":"10.1136\/ijgc-2023-004454_bb0115","doi-asserted-by":"crossref","first-page":"100085","DOI":"10.1016\/j.modpat.2022.100085","article-title":"Grade and estrogen receptor expression identify a subset of no specific molecular profile endometrial Carcinomas at a very low risk of disease-specific death","volume":"36","author":"Jamieson","year":"2023","journal-title":"Mod Pathol"},{"key":"10.1136\/ijgc-2023-004454_bb0120","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/j.ygyno.2010.10.015","article-title":"Phase II study of Fulvestrant in recurrent\/metastatic endometrial carcinoma: a gynecologic oncology group study","volume":"120","author":"Covens","year":"2011","journal-title":"Gynecol Oncol"},{"key":"10.1136\/ijgc-2023-004454_bb0125","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1016\/j.ygyno.2013.02.039","article-title":"Phase II study of Fulvestrant 250 mg\/month in patients with recurrent or metastatic endometrial cancer: a study of the Arbeitsgemeinschaft Gyn\u00e4kologische Onkologie","volume":"129","author":"Emons","year":"2013","journal-title":"Gynecol Oncol"},{"key":"10.1136\/ijgc-2023-004454_bb0130","doi-asserted-by":"crossref","first-page":"109870","DOI":"10.1016\/j.biopha.2020.109870","article-title":"Cdk4\/RB\/E2Fs axis as potential therapeutic target of endometrial cancer","volume":"125","author":"Hu","year":"2020","journal-title":"Biomed Pharmacother"},{"key":"10.1136\/ijgc-2023-004454_bb0135","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1054\/bjoc.1999.0980","article-title":"The role of P16-Cyclin d\/CDK-pRb pathway in the tumorigenesis of Endometrioid-type endometrial carcinoma","volume":"82","author":"Tsuda","year":"2000","journal-title":"Br J Cancer"},{"key":"10.1136\/ijgc-2023-004454_bb0140","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.ygyno.2007.04.032","article-title":"The relationship between Histology and outcome in advanced and recurrent endometrial cancer patients participating in first-line chemotherapy trials: a gynecologic oncology group study","volume":"106","author":"McMeekin","year":"2007","journal-title":"Gynecol Oncol"},{"key":"10.1136\/ijgc-2023-004454_bb0145","doi-asserted-by":"crossref","first-page":"3841","DOI":"10.1200\/JCO.20.01076","article-title":"Carboplatin and paclitaxel for advanced endometrial cancer: final overall survival and adverse event analysis of a phase III trial (NRG oncology\/Gog0209)","volume":"38","author":"Miller","year":"2020","journal-title":"J Clin Oncol"},{"key":"10.1136\/ijgc-2023-004454_bb0150","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1056\/NEJMoa2108330","article-title":"Lenvatinib plus Pembrolizumab for advanced endometrial cancer","volume":"386","author":"Makker","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1136\/ijgc-2023-004454_bb0155","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1016\/j.ygyno.2023.01.025","article-title":"Molecular subtype stratified outcomes according to adjuvant therapy in endometrial cancer","volume":"170","author":"Jamieson","year":"2023","journal-title":"Gynecol Oncol"},{"key":"10.1136\/ijgc-2023-004454_bb0160","doi-asserted-by":"crossref","first-page":"359","DOI":"10.3389\/fonc.2019.00359","article-title":"Anti-estrogen treatment in endometrial cancer: A systematic review","volume":"9","author":"ENITEC","year":"2019","journal-title":"Front Oncol"},{"key":"10.1136\/ijgc-2023-004454_bb0165","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1016\/j.ygyno.2017.07.002","article-title":"Is hormonal therapy effective in advanced endometrial cancer? A systematic review and meta-analysis","volume":"147","author":"Ethier","year":"2017","journal-title":"Gynecol Oncol"},{"key":"10.1136\/ijgc-2023-004454_bb0170","doi-asserted-by":"crossref","first-page":"1736","DOI":"10.1200\/JCO.1999.17.6.1736","article-title":"Oral Medroxyprogesterone acetate in the treatment of advanced or recurrent endometrial carcinoma: a dose-response study by the gynecologic oncology group","volume":"17","author":"Thigpen","year":"1999","journal-title":"J Clin Oncol"},{"key":"10.1136\/ijgc-2023-004454_bb0175","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/j.ygyno.2004.06.045","article-title":"Hormonal therapy for the management of grade 1 endometrial adenocarcinoma: a literature review","volume":"95","author":"Ramirez","year":"2004","journal-title":"Gynecol Oncol"},{"key":"10.1136\/ijgc-2023-004454_bb0180","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1016\/j.ygyno.2014.01.015","article-title":"Temsirolimus with or without Megestrol acetate and tamoxifen for endometrial cancer: a gynecologic oncology group study","volume":"132","author":"Fleming","year":"2014","journal-title":"Gynecol Oncol"},{"key":"10.1136\/ijgc-2023-004454_bb0185","doi-asserted-by":"crossref","first-page":"1811","DOI":"10.1136\/ijgc-2020-001309","article-title":"Improving response to Progestin treatment of low-grade endometrial cancer","volume":"30","author":"Baxter","year":"2020","journal-title":"Int J Gynecol Cancer"},{"key":"10.1136\/ijgc-2023-004454_bb0190","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1200\/JCO.2001.19.2.364","article-title":"Tamoxifen in the treatment of advanced or recurrent endometrial carcinoma: a gynecologic oncology group study","volume":"19","author":"Thigpen","year":"2001","journal-title":"J Clin Oncol"},{"key":"10.1136\/ijgc-2023-004454_bb0195","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.ygyno.2003.11.008","article-title":"Phase II trial of alternating courses of Megestrol acetate and tamoxifen in advanced endometrial carcinoma: a gynecologic oncology group study","volume":"92","author":"Fiorica","year":"2004","journal-title":"Gynecol Oncol"},{"key":"10.1136\/ijgc-2023-004454_bb0200","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.ygyno.2003.09.018","article-title":"Phase II study of Medroxyprogesterone acetate plus tamoxifen in advanced endometrial carcinoma: a gynecologic oncology group study","volume":"92","author":"Whitney","year":"2004","journal-title":"Gynecol Oncol"},{"key":"10.1136\/ijgc-2023-004454_bb0205","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1006\/gyno.2000.5865","article-title":"A phase II trial of anastrozole in advanced recurrent or persistent endometrial carcinoma: a gynecologic oncology group study","volume":"78","author":"Rose","year":"2000","journal-title":"Gynecol Oncol"},{"key":"10.1136\/ijgc-2023-004454_bb0210","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.ygyno.2019.05.007","article-title":"Phase 2 study of anastrozole in recurrent estrogen (ER)\/Progesterone (PR) positive endometrial cancer: the PARAGON trial - ANZGOG 0903","volume":"154","author":"Mileshkin","year":"2019","journal-title":"Gynecol Oncol"},{"key":"10.1136\/ijgc-2023-004454_bb0215","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1016\/j.ygyno.2021.12.031","article-title":"A randomized phase II trial of everolimus and Letrozole or hormonal therapy in women with advanced, persistent or recurrent endometrial carcinoma: A GOG foundation study","volume":"164","author":"Slomovitz","year":"2022","journal-title":"Gynecol Oncol"},{"key":"10.1136\/ijgc-2023-004454_bb0220","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1038\/bjc.2016.430","article-title":"Phase II study of the Pi3K inhibitor Bkm120 in patients with advanced or recurrent endometrial carcinoma: a stratified type I-type II study from the GINECO group","volume":"116","author":"Heudel","year":"2017","journal-title":"Br J Cancer"},{"key":"10.1136\/ijgc-2023-004454_bb0225","doi-asserted-by":"crossref","first-page":"930","DOI":"10.1200\/JCO.2014.58.3401","article-title":"Phase II study of everolimus and Letrozole in patients with recurrent endometrial carcinoma","volume":"33","author":"Slomovitz","year":"2015","journal-title":"J Clin Oncol"},{"key":"10.1136\/ijgc-2023-004454_bb0230","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1001\/jamaoncol.2022.1047","article-title":"Safety and efficacy of the mTOR inhibitor, Vistusertib, combined with anastrozole in patients with hormone receptor-positive recurrent or metastatic endometrial cancer: the VICTORIA multicenter, open-label, phase 1\/2 randomized clinical trial","volume":"8","author":"Heudel","year":"2022","journal-title":"JAMA Oncol"},{"key":"10.1136\/ijgc-2023-004454_bb0235","doi-asserted-by":"crossref","DOI":"10.1016\/j.annonc.2020.08.2258","article-title":"Lba28 A randomised double-blind placebo-controlled phase II trial of Palbociclib combined with Letrozole (L) in patients (Pts) with oestrogen receptor-positive (ER+) advanced\/recurrent endometrial cancer (EC): NSGO-PALEO \/ ENGOT-En3 trial","volume":"31","author":"Mirza","year":"2020","journal-title":"Ann Oncol"},{"key":"10.1136\/ijgc-2023-004454_bb0240","doi-asserted-by":"crossref","DOI":"10.1136\/esmoopen-2020-000926","article-title":"Phase II trial of Ribociclib and Letrozole in patients with Relapsed oestrogen receptor-positive ovarian or endometrial cancers","volume":"5","author":"Colon-Otero","year":"2020","journal-title":"ESMO Open"},{"key":"10.1136\/ijgc-2023-004454_bb0245","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1200\/JCO.22.00628","article-title":"A phase II, two-stage study of Letrozole and Abemaciclib in estrogen receptor-positive recurrent endometrial cancer","volume":"41","author":"Konstantinopoulos","year":"2023","journal-title":"J Clin Oncol"},{"key":"10.1136\/ijgc-2023-004454_bb0250","author":"Lorusso","year":"2022"},{"key":"10.1136\/ijgc-2023-004454_bb0255","first-page":"73","article-title":"Cyclin D-dependent Kinases, Ink4 inhibitors and cancer","volume":"1602","author":"Ortega","year":"2002","journal-title":"Biochim Biophys Acta"},{"key":"10.1136\/ijgc-2023-004454_bb0260","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/S1470-2045(14)71159-3","article-title":"The Cyclin-dependent kinase 4\/6 inhibitor Palbociclib in combination with Letrozole versus Letrozole alone as first-line treatment of oestrogen receptor-positive, Her2-negative, advanced breast cancer (PALOMA-1\/TRIO-18): a randomised phase 2 study","volume":"16","author":"Finn","year":"2015","journal-title":"Lancet Oncol"},{"key":"10.1136\/ijgc-2023-004454_bb0265","doi-asserted-by":"crossref","first-page":"1925","DOI":"10.1056\/NEJMoa1607303","article-title":"Palbociclib and Letrozole in advanced breast cancer","volume":"375","author":"Finn","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1136\/ijgc-2023-004454_bb0270","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1056\/NEJMoa1903765","article-title":"Overall survival with Ribociclib plus endocrine therapy in breast cancer","volume":"381","author":"Im","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1136\/ijgc-2023-004454_bb0275","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1001\/jamaoncol.2019.4782","article-title":"The effect of Abemaciclib plus Fulvestrant on overall survival in hormone receptor-positive, Erbb2-negative breast cancer that progressed on endocrine therapy-MONARCH 2: A randomized clinical trial","volume":"6","author":"Sledge","year":"2020","journal-title":"JAMA Oncol"},{"key":"10.1136\/ijgc-2023-004454_bb0280","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1016\/j.ygyno.2012.02.037","article-title":"Hormonal therapy for recurrent low-grade Serous carcinoma of the ovary or Peritoneum","volume":"125","author":"Gershenson","year":"2012","journal-title":"Gynecol Oncol"},{"key":"10.1136\/ijgc-2023-004454_bb0285","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1200\/JCO.2016.71.0632","article-title":"Hormonal maintenance therapy for women with low-grade Serous cancer of the ovary or Peritoneum","volume":"35","author":"Gershenson","year":"2017","journal-title":"J Clin Oncol"},{"key":"10.1136\/ijgc-2023-004454_bb0290","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1016\/j.ygyno.2007.11.013","article-title":"Neoadjuvant chemotherapy for low-grade Serous carcinoma of the ovary or Peritoneum","volume":"108","author":"Schmeler","year":"2008","journal-title":"Gynecol Oncol"},{"key":"10.1136\/ijgc-2023-004454_bb0295","unstructured":"ClinicalTrials.gov . Letrozole with or without paclitaxel and carboplatin in treating patients with stage II-IV ovarian, Fallopian tube, or primary peritoneal cancer. N.R.G. Oncology, National Cancer Institute (NCI). Available: https:\/\/ClinicalTrials.gov\/show\/NCT04095364 [Accessed 15 Dec 2022]."},{"key":"10.1136\/ijgc-2023-004454_bb0300","unstructured":"ClinicalTrials.gov . Ribociclib and Letrozole treatment in ovarian cancer. Sponsor\/Collaborators: Gynecologic Oncology Group, Novartis, G.O.G. Foundation. Available: https:\/\/ClinicalTrials.gov\/show\/NCT03673124 Accessed:15 [Accessed Dec 2022]."},{"key":"10.1136\/ijgc-2023-004454_bb0305","author":"ClinicalTrials.gov","year":"2022","journal-title":"Letrozole for estrogen\/progesterone receptor positive low-grade Serous epithelial ovarian cancer (LEPRE trial). sponsor\/collaborators: Ente Ospedaliero Ospedali Galliera, Istituto Di Ricerche Farmacologiche Mario Negri, Humanitas hospital, Italy"},{"key":"10.1136\/ijgc-2023-004454_bb0310","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.1002\/cncr.34661","article-title":"Functional estrogen receptor signal Transduction pathway activity and Antihormonal therapy response in low-grade ovarian carcinoma","volume":"129","author":"Hendrikse","year":"2023","journal-title":"Cancer"},{"key":"10.1136\/ijgc-2023-004454_bb0315","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1158\/1535-7163.MCT-19-0318","article-title":"Estrogen receptor pathway activity score to predict clinical response or resistance to Neoadjuvant endocrine therapy in primary breast cancer","volume":"19","author":"Inda","year":"2020","journal-title":"Mol Cancer Ther"},{"key":"10.1136\/ijgc-2023-004454_bb0320","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1038\/s41416-020-0925-4","article-title":"Oestrogen receptor pathway activity is associated with outcome in endometrial cancer","volume":"123","author":"van Weelden","year":"2020","journal-title":"Br J Cancer"}],"container-title":["International Journal of Gynecological Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1048891X24017729?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1048891X24017729?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/ijgc-2023-004454","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,23]],"date-time":"2025-07-23T01:28:30Z","timestamp":1753234110000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1048891X24017729"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11]]},"references-count":63,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2023,11]]}},"alternative-id":["S1048891X24017729"],"URL":"https:\/\/doi.org\/10.1136\/ijgc-2023-004454","relation":{},"ISSN":["1048-891X"],"issn-type":[{"value":"1048-891X","type":"print"}],"subject":[],"published":{"date-parts":[[2023,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Evolving treatment paradigms in metastatic or recurrent low-grade endometrial cancer: When is hormonal-based therapy the preferred option?","name":"articletitle","label":"Article Title"},{"value":"International Journal of Gynecological Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1136\/ijgc-2023-004454","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, an indication of whether changes were made, and the use is non-commercial. See: http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/.","name":"copyright","label":"Copyright"}]}}